Skip to main content
. 2019 Apr 9;40(11):1415–1426. doi: 10.1093/carcin/bgz070

Figure 6.

Figure 6.

β-hCG induces drug resistance in BRCA1 mutant cells. (A) Colony-forming ability (adherent colonies) of HCC1937 and HCC1937/wt BRCA1 in the presence or in the absence of 5 IU of β-hCG after treating with indicated doses of 17AAG for 72 h. (B) Cell proliferation of HCC1937 and HCC1937/wt BRCA1 cells treated with increasing concentrations of 17AAG for 96 h in the presence or in the absence of β-hCG as assessed by MTS assay. (C) Cell proliferation of β-hCG-silenced HCC1937 cells treated with increasing concentrations of 17AAG for 72 h as assessed by MTS assay. (D) Cell proliferation of BRCA1 stably silenced HCC1937 cells treated with increasing concentrations of 17AAG for 72 h as assessed by MTS assay. (E) The level of phosphorylation of TGFBRII in HCC1937 and HCC1937/wt BRCA1cells treated with and/or without 17AAG in the presence or absence of β-hCG. (F) Western blot analysis of P-CHK2 and γ-H2A.X in HCC1937 and MCF7 treated with 17AAG or SB-431542 or combination of both. (G) Cell proliferation of HCC1937 and MCF7 treated with combination of 17AAG and SB-431542 as assessed by MTS assay. Full blots of cropped images are included in supplementary information.